AstraZeneca Partners with UVA to Accelerate Pre-Clinical Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4h ago
0mins
Source: seekingalpha
- Research Collaboration Agreement: AstraZeneca's partnership with the University of Virginia aims to accelerate pre-clinical research across oncology, immunology, cardiovascular, metabolism, and infectious diseases, which is expected to significantly enhance the pace of drug discovery and translational research.
- Initial Research Program: The first program under this agreement will focus on preclinical research for C. difficile, leveraging UVA's capabilities in high-throughput screening, advanced imaging, computational modeling, and biostatistics to drive innovation in this area.
- Investment Plans: AstraZeneca plans to invest several billion dollars in a new manufacturing plant near Charlottesville, Virginia, by 2025, which will not only enhance its production capacity but also positively impact the local economy.
- Strategic Implications: This collaboration and investment demonstrate AstraZeneca's long-term commitment to the biopharmaceutical sector, aiming to accelerate the development of new therapies through close collaboration with academia to address global health challenges.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 102.75 USD with a low forecast of 95.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 95.600
Low
95.00
Averages
102.75
High
108.00
Current: 95.600
Low
95.00
Averages
102.75
High
108.00
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
